101
|
Jung H, Hong S, Park J, Park M, Sun J, Lee S, Ahn J, Ahn M, Park K. MA19.06 Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.659] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
102
|
Park K. P2.13-13 Should Visceral Pleural Invasion Be Prognostic Factor in Patient with Smaller Sized Adenocarcinoma? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
103
|
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan S, Loong H, Bauer T, Kim Y, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho B, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Moreno Garcia V, Medioni J, Matrana M, Rolfo C, Lee D, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Staal Rohrberg K, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, B.Nair, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.059] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
104
|
Ku B, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
105
|
Shin S, Jung M, Song J, Kim J, Park K, Kim J, Lim H, Cho I, Won H, Lee W, Kim S, Kim T, Kim C, Lip GYH. P5350Atrial fibrillation prediction using P wave signal-averaged ECG in patients with embolic stroke of undetermined source. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Approximately 10–25% of ischemic strokes are of unknown origin. Determining their potential association with subclinical atrial fibrillation (SCAF) is important for proper secondary prevention. We investigated whether SCAF can be predicted by assessing the atrial substrate with signal-averaged electrocardiography (SAECG).
Methods
Between April 2015 and February 2018, we recruited 125 consecutive patients with embolic stroke of undetermined source (ESUS) and 125 patients with paroxysmal atrial fibrillation (AF) patients as control. All participants underwent P wave SAECG at baseline and ESUS patients were followed up with ECG and Holter ECG, at baseline, 3, 6, and 12 months after discharge, and every 12 months thereafter.
Results
In the ESUS group (69 males, 68.4±12.1 years), 32 (25.6%) patients were diagnosed with SCAF during follow-up. There were no significant differences between both groups in terms of P wave duration [PWD] (ESUS vs. AF, P=0.321). PWD demonstrated a significant predictive efficacy for SCAF detection during follow-up (C-index of standard PWD=0.657, 95% confidence interval (CI) 0.552–0.761, P=0.008).
Stroke recurrence occurred in 22 patients (17.6%) and was significantly associated with PWD but not SCAF (odds ratio 2.756, 95% CI 1.061–7.161, P=0.037).
Conclusion
PWD, an ECG biomarker associated with atrial substrate directly contributes to AF and ESUS, is useful for predicting SCAF. The potential for using this simple ECG biomarker for screening for SCAF amongst ESUS patients merits further exploration.
Collapse
Affiliation(s)
- S Shin
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - M Jung
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - J Song
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - J Kim
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - K Park
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - J Kim
- Korea University Ansan Hospital, Cardiology, Ansan-Si, Korea (Republic of)
| | - H Lim
- Hallym University Sacred Heart Hospital, Anyang-Si, Gyeonggi-Do, Korea (Republic of)
| | - I Cho
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - H Won
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - W Lee
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - S Kim
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - T Kim
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - C Kim
- Chung-Ang University Hospital, Seoul, Korea (Republic of)
| | - G Y H Lip
- University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
106
|
Ku B, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P1.04-06 Tumor Microenvironment Landscape in Lung Adenocarcinoma by Single-Cell Sequencing. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
107
|
Lee J, Ku B, Shim J, Choi Y, Sun J, Lee S, Ahn J, Park K, Ahn M. P2.14-54 High Incidence of CNS Metastases in Advanced or Recurrent Non-Small Cell Lung Cancer Patients with RET Fusion. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
108
|
Lee S, Pathak K, Mcgilvrey M, Mansfield K, Cridebring D, Roe D, Whitsett T, Pirrotte P, Sun J, Ahn J, Ahn M, Park K. P2.12-14 A Pilot Study of Serial Plasma Metabolomics in Small Cell Lung Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
109
|
Kim J, Kim Y, Park K, Jeong Y, Choi J, Chung SJ, Shin Y, Hong S. Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective met inhibitor, in gastric and non-small cell lung cancer models. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
110
|
Ahn M, Park S, Hong S, Park J, Park M, Jung H, Sun J, Lee S, Ahn J, Park K. MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
111
|
Kim Y, Kim C, Lee S, Lee H, Kim H, Kim K, Sun J, Ahn J, Ahn M, Park K. OA14.07 Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
112
|
Ku B, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P2.09-07 Multiple Immunohistochemistry of Non-Small Cell Lung Cancers Reveals Distinct Immune Context. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
113
|
Barlesi F, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JCH, Bajars M, Ruisi M, Manitz J, Park K. Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
114
|
Chae D, Kim SY, Song Y, Baek W, Shin H, Park K, Han DW. Dynamic predictive model for postoperative nausea and vomiting for intravenous fentanyl patient-controlled analgesia. Anaesthesia 2019; 75:218-226. [PMID: 31531854 DOI: 10.1111/anae.14849] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/15/2019] [Indexed: 02/07/2023]
Abstract
Postoperative nausea and vomiting is the most common side-effect of opioid-based intravenous patient-controlled analgesia. Apfel's simplified risk score is popular but it has some limitations. We developed and validated a dynamic predictive model for nausea or vomiting up to 48 postoperative hours, available as an online web application. Fentanyl was used by 22,144 adult patients for analgesia after non-cardiac surgery under general anaesthesia: we randomly divided them into development (80%) and validation (20%) cohorts, repeated 100 times. We used linear discriminant analysis to select variables for multivariate logistic regression. The incidences of postoperative nausea or vomiting were: 0-48 h, 5691/22,144 (26%); 0-6 h, 2749/22,144 (12%); 6-12 h, 2687/22,144 (12%); 12-18 h, 2624/22,144 (12%); 18-24 h, 1884/22,144 (9%); and 24-48 h, 1082/22,144 (5%). The median (95%CI) area under the receiver operating characteristic curve was 0.72 (0.71-0.73) up to 48 postoperative hours compared with 0.65 (0.64-0.66) for the Apfel model, p < 0.001. The equivalent areas for 0-6 h, 6-12 h, 12-18 h, 18-24 h and 24-48 h were: 0.70 (0.69-0.72); 0.71 (0.69-0.73); 0.69 (0.68-0.71); 0.70 (0.67-0.72); and 0.69 (0.66-0.71), respectively. Our web application allows clinicians to calculate incidences of nausea and vomiting in patients receiving intravenous fentanyl for patient-controlled analgesia.
Collapse
Affiliation(s)
- D Chae
- Department of Pharmacology, Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - S Y Kim
- Department of Anaesthesiology and Pain Medicine, Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Y Song
- Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - W Baek
- Department of Anaesthesiology and Pain Medicine, Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - H Shin
- Department of Anaesthesiology and Pain Medicine, Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - K Park
- Department of Pharmacology, Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - D W Han
- Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
115
|
Hwang J, An H, Yoon S, Park K. P14.27 The significance of multicentric noncontrast-enhancing lesions distant from surgically resected glioblastoma: Case series of 3 patients. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma is the most malignant primary brain tumor. The tumor location and multiplicity plays an important role in surgical and further treatment. The incidence of multiple lesions at the time of diagnosis was known as 1–20%, which showed a poor prognostic factor. Most researches has focused on multiple contrast-enhancing lesions, however, multicentric non-enhancing lesions distant from glioblastoma has been rarely evaluated. The authors reported the case series of the patient who showed multicentric non contrast-enhancing lesions without connection to histologically-proven glioblastoma.
MATERIAL AND METHODS
Multicentric non contrast-enhancing lesions were defined as areas of FLAIR hyperintensity and mass effect without post-contrast enhancement, separated from the histologically-proven glioblastoma in a newly diagnosed disease. Three patients who showed distant non-enhancing lesions with appearance of a multicentric low-grade glioma were included in this study. The typical enhancing lesions were surgically resected and standard chemo-radiotherapy was followed in all patients.
RESULTS
All patients were male and their age was 38, 60 and 65 years old respectively. Multicentric tumor location was as follows: Case 1, left frontal lobe with non-enhancing lesion in left parahippocampal gyrus; Case 2, left parietal with non-enhancing lesion in left anteromedial temporal lobe; Case 3, left thalamus with non-enhancing lesions in both basal frontal and right temporal lobe. Pathologically, the resected enhancing tumor revealed glioblastoma in 2 patients and diffuse midline glioma in 1. All tumors were IDH-wild type. The resected enhanced lesion showed no progression but all non-enhancing lesions developed contrast-enhancing tumors at 3, 13 and 17 months after initial treatment, with high tracer uptake on 18FDG-PET or 18FDOPA-PET. Despite multidisciplinary treatment, two patients died from disease progression at 30 and 32 months after diagnosis and one patient is still alive with overall survival of 15 months.
CONCLUSION
The appearance of multicentric non-enhancing lesions distant from a typically enhancing tumor showed an uncommon finding in glioblastoma and poor prognostic features. These lesions progress faster than expected for a low-grade glioma. These lesions should be distinguished from typical low-grade glioma and should be considered more advanced lesions than their appearances suggest.
Collapse
Affiliation(s)
- J Hwang
- Dept of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea, Republic of
| | - H An
- Dept of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea, Republic of
| | - S Yoon
- Dept of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea, Republic of
| | - K Park
- Dept of Neurosurgery, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
| |
Collapse
|
116
|
|
117
|
Shin K, Park H, Kim B, Lee Y, Kim S, Park K. LB1120 Naturally occurring phenolic compounds protect human keratinocytes against diesel exhaust particle-induced cell damage. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.06.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
118
|
Jung J, Park K, Shin SH, Lee JY, Kim MN, Kim SH. The pitfall of cohort isolation in an outbreak of linezolid-resistant, vancomycin-resistant enterococci. Clin Microbiol Infect 2019; 25:1568-1569. [PMID: 31449869 DOI: 10.1016/j.cmi.2019.08.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 08/15/2019] [Accepted: 08/17/2019] [Indexed: 11/28/2022]
Affiliation(s)
- J Jung
- Office for Infection Control, Asan Medical Centre, Seoul, Republic of Korea; Department of Infectious Diseases, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - K Park
- Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - S-H Shin
- Office for Infection Control, Asan Medical Centre, Seoul, Republic of Korea
| | - J-Y Lee
- Office for Infection Control, Asan Medical Centre, Seoul, Republic of Korea
| | - M-N Kim
- Office for Infection Control, Asan Medical Centre, Seoul, Republic of Korea; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
| | - S-H Kim
- Office for Infection Control, Asan Medical Centre, Seoul, Republic of Korea; Department of Infectious Diseases, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
| |
Collapse
|
119
|
Nam Y, Park K, Lee S, Ha J, Kim J, Yun H, Han S. SUN-337 ASSOCIATION BETWEEN WEIGHT REDUCTION AND DEVELOPING CARDIOVASCULAR EVENT AMONG THE GENERAL POPULATION. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
120
|
LEE G, Han S, Joo Y, Nam Y, Park K. SAT-257 THE ROLE OF NON-TRADITIONAL RISK FACTORS AND BIOMARKERS IN PREDICTION OF CARDIOVASCULAR EVENTS AND MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM THE KNOW-CKD. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
121
|
Lee S, Nam K, Park K, Ha J, Nam Y, Lee S, Han S. SUN-028 PROGNOSTIC VALUE OF MESANGIAL C3 AND C4d DEPOSITION IN IgA NEPHROPATHY. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
122
|
Duer M, Schmidt A, Pybus JR, Segarra EP, Hrnjic A, Denniston AW, Weiss R, Hen O, Piasetzky E, Weinstein LB, Barnea N, Korover I, Cohen EO, Hakobyan H, Adhikari S, Angelini G, Battaglieri M, Beck A, Bedlinskiy I, Biselli AS, Boiarinov S, Brooks W, Burkert VD, Cao F, Carman DS, Celentano A, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Cortes O, Crede V, Cruz Torres R, D'Angelo A, Dashyan N, De Sanctis E, De Vita R, Deur A, Diehl S, Djalali C, Dupre R, Duran B, Egiyan H, El Alaoui A, El Fassi L, Eugenio P, Filippi A, Forest TA, Gilfoyle GP, Giovanetti KL, Girod FX, Golovatch E, Gothe RW, Griffioen KA, Guo L, Hafidi K, Hanretty C, Harrison N, Hattawy M, Hauenstein F, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jo HS, Joo K, Kabir ML, Keller D, Khachatryan M, Khanal A, Khandaker M, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, Laskaris G, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, McKinnon B, Mey-Tal Beck S, Mirazita M, Mokeev V, Montgomery RA, Movsisyan A, Munoz Camacho C, Mustapha B, Nadel-Turonski P, Niccolai S, Niculescu G, Osipenko M, Ostrovidov AI, Paolone M, Paremuzyan R, Park K, Pasyuk E, Patsyuk M, Phelps W, Pogorelko O, Prok Y, Protopopescu D, Ripani M, Rizzo A, Rosner G, Rossi P, Sabatié F, Schmookler BA, Schumacher RA, Sharabian Y, Skorodumina I, Sokhan D, Sparveris N, Stepanyan S, Strauch S, Taiuti M, Tan JA, Tyler N, Ungaro M, Voskanyan H, Voutier E, Wang R, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW, Zheng X. Direct Observation of Proton-Neutron Short-Range Correlation Dominance in Heavy Nuclei. Phys Rev Lett 2019; 122:172502. [PMID: 31107086 DOI: 10.1103/physrevlett.122.172502] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 03/11/2019] [Indexed: 06/09/2023]
Abstract
We measured the triple coincidence A(e,e^{'}np) and A(e,e^{'}pp) reactions on carbon, aluminum, iron, and lead targets at Q^{2}>1.5 (GeV/c)^{2}, x_{B}>1.1 and missing momentum >400 MeV/c. This was the first direct measurement of both proton-proton (pp) and neutron-proton (np) short-range correlated (SRC) pair knockout from heavy asymmetric nuclei. For all measured nuclei, the average proton-proton (pp) to neutron-proton (np) reduced cross-section ratio is about 6%, in agreement with previous indirect measurements. Correcting for single-charge exchange effects decreased the SRC pairs ratio to ∼3%, which is lower than previous results. Comparisons to theoretical generalized contact formalism (GCF) cross-section calculations show good agreement using both phenomenological and chiral nucleon-nucleon potentials, favoring a lower pp to np pair ratio. The ability of the GCF calculation to describe the experimental data using either phenomenological or chiral potentials suggests possible reduction of scale and scheme dependence in cross-section ratios. Our results also support the high-resolution description of high-momentum states being predominantly due to nucleons in SRC pairs.
Collapse
Affiliation(s)
- M Duer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J R Pybus
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Hrnjic
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A W Denniston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - R Weiss
- The Racah Institute of Physics, The Hebrew University, Jerusalem, Israel
| | - O Hen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Barnea
- The Racah Institute of Physics, The Hebrew University, Jerusalem, Israel
| | - I Korover
- Nuclear Research Centre Negev, Beer-Sheva, Israel
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - H Hakobyan
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | | | | | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- Fairfield University, Fairfield Connecticut 06824, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Universita' di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - L Clark
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P L Cole
- Catholic University of America, Washington, DC, 20064, USA
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Blvd, PO Box 10009, Beaumont, Texas 77710, USA
| | | | - O Cortes
- The George Washington University, Washington, DC, 20052, USA
| | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - R Cruz Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - R Dupre
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - Burcu Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Egiyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - T A Forest
- Idaho State University, Pocatello, Idaho 83209, USA
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - K L Giovanetti
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - F X Girod
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - L Guo
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - C Hanretty
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Hattawy
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- The George Washington University, Washington, DC, 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - K Joo
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, DC, 20064, USA
| | - V Kubarovsky
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - G Laskaris
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - N Markov
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - V Mokeev
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - B Mustapha
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - K Park
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - E Pasyuk
- Arizona State University, Tempe, Arizona 85287-1504, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Patsyuk
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - W Phelps
- The George Washington University, Washington, DC, 20052, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Sabatié
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - B A Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Strauch
- The George Washington University, Washington, DC, 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- INFN, Sezione di Genova, 16146 Genova, Italy
- Universita di Genova, Dipartimento di Fisica, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - R Wang
- Institut de Physique Nucl'eaire, IN2P3-CNRS, Universit'e Paris-Sud, Universit'e Paris-Saclay, F-91406 Orsay, France
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M H Wood
- Canisius College, Buffalo, New York 14208, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - N Zachariou
- University of York, York YO10, United Kingdom
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22901, USA
| |
Collapse
|
123
|
Mauro T, Celli A, Cho R, Lambert W, Park K, Pitchford M, Gordon M, Lee E, Tsai K, Cleaver J, Arron S. 504 CERKL expression enhances survival in cutaneous squamous cell carcinoma. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
124
|
Shin K, Kim K, Cho Y, Ikushiro H, Yano T, Holleran W, Park K, Uchida Y. 298 Both sphingosine kinase 1 and 2 coordinately regulate cathelicidin antimicrobial peptide production during keratinocyte differentiation. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
125
|
Shin K, Yoon S, Jung J, Hwang E, Jeong S, Chung H, Park K. 466 Stimulation of autophagy attenuated Propionibacterium acnes-induced inflammatory responses in cultured skin cells. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
126
|
Shin K, Park K, Jeong S, Park B, Uchida Y, Wakefield J, Crumrine D, Meyer J, Elias P. 647 Basis for the link between atopic dermatitis and autism. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
127
|
Owonikoko T, Kim H, Govindan R, Ready N, Reck M, Peters S, Dakhil S, Navarro A, Rodriguez-Cid J, Schenker M, Lee J, Gutierrez V, Percent I, Morgensztern D, Fairchild J, Baudelet C, Park K. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
|
128
|
Le T, Park J, Jeon Y, Park K, Hong K, Cho S. 03:27 PM Abstract No. 96 Prevalence of May-Thurner variants in patients with symptomatic May-Thurner syndrome. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
129
|
Ahn HK, Park S, Hyun SH, Park K, Lee E, Kim JY, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im YH, Park YH. Abstract P3-08-12: PIK3CA mutations in breast cancer: Mutational landscape and clinical implications in ER+/HER2- subtype. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-08-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: PIK3CA mutation is one of the most frequent genomic alterations in breast cancer. We evaluated PIK3CA mutational status including spatial and temporal heterogeneity, clinical characteristics and prognostic impact focused on ER+/HER2- subtype.
Methods: We performed targeted ultra-deep sequencing (CancerSCAN™) of breast cancer tissue in a prospective cohort. Burden of disease was assessed by metabolic tumor volume(MTV) in 18F-FDG-PET scan. Association with clinical characteristics or survival were tested in ER+/HER2- subtype, using Chi square test or Kaplan-Meier method.
Results: PIK3CA analyses were performed in 1274 breast cancer specimens from 1091 patients. 957 patients had early breast cancer. PIK3CA alterations were found in 397 patients(36.3%), and frequency of PIK3CA mutation was significantly lower in triple negative breast cancer(19.0%), compared with 40.4% in ER+/HER2-, 40.9% in ER+/HER2+, and 45.2% in ER-/HER2+ subtype(p<0.0001). 158 patients had more than two biopsies. Among 92 patients with second biopsy within one month, 11%(10/92) had spatial heterogeneity of PIK3CA mutation. After neoadjuvant chemotherapy, 10%(3/30) of patients had change of PIK3CA mutational status. Serial biopsy at time of recurrence revealed loss or gain of PIK3CA mutation in 10 out of 59 patients (17%). In ER+/HER2- subtype, PIK3CA had a trend toward longer distant disease free survival without statistical significance. In patients with stage IV ER+/HER2- disease, PIK3CA hotspot mutations were associated with significant longer overall survival(OS) (71.0 vs. 37.8 months, p=0.048) and better progression free survival(PFS) at 1st line palliative treatment (37.7 vs. 9.4 months, p = 0.0004). Frequency of symptomatic recurrence, recurrence as oligometastases, and specific metastatic sites were not associated with PIK3CA mutational status, except that bone metastases at first distant metastases was less prevalent in patients with PIK3CA hotspot mutations(35.6% vs. 53.8% in PIK3CA wt, p=0.048). Metabolic tumor volume(MTV) at time of first distant metastases was not associated with presence of PIK3CA mutation.
Conclusion: We observed variations in PIK3CA mutational status in more than 10% of patients with >1 repeated biopsy. In stage IV ER+/HER2- disease, PIK3CA hotspot mutation seemed to be associated with longer PFS and OS, however metabolic tumor burden was not associated with PIK3CA alterations.
Citation Format: Ahn HK, Park S, Hyun SH, Park K, Lee E, Kim J-Y, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im Y-H, Park YH. PIK3CA mutations in breast cancer: Mutational landscape and clinical implications in ER+/HER2- subtype [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-08-12.
Collapse
Affiliation(s)
- HK Ahn
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SH Hyun
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - K Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - E Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J-Y Kim
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SJ Nam
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SW Kim
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JE Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SK Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JH Yu
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JS Ahn
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y-H Im
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - YH Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
130
|
Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JCH, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 2019; 30:171-210. [PMID: 30596843 DOI: 10.1093/annonc/mdy554] [Citation(s) in RCA: 188] [Impact Index Per Article: 37.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.
Collapse
Affiliation(s)
- Y-L Wu
- Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
| | - D Planchard
- Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France
| | - S Lu
- Shanghai Chest Hospital, Shanghai, P.R. China
| | - H Sun
- Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, P.R. China
| | - N Yamamoto
- Department of Internal Medicine 3, Wakayama Medical University, Wakayama, Japan
| | - D-W Kim
- Seoul National University Hospital, Seoul, Korea
| | - D S W Tan
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore
| | - J C-H Yang
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
| | - M Azrif
- Department of Radiotherapy & Oncology, Prince Court Medical Centre, Kuala Lumpur, Malaysia
| | - T Mitsudomi
- Faculty of Medicine, Department of Thoracic Surgery, Kindai University, Osaka-Sayama, Japan
| | - K Park
- Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - R A Soo
- Department of Haematology-Oncology, National University Hospital, Singapore, Singapore
| | - J W C Chang
- Division of Haematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung, Taiwan
| | - A Alip
- Faculty of Medicine, Department of Clinical Oncology, University of Malaya, Kuala Lumpur, Malaysia
| | - S Peters
- Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | | |
Collapse
|
131
|
Yang S, Lee J, Park K, Kim J. Papillary thyroid carcinoma with foci of undifferentiated carcinoma: a case report. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
132
|
Chung W, Jung Y, Lee K, Park J, Sheen S, Park K. CXCR3 ligands in pleural fluid as markers for the diagnosis of tuberculous pleural effusion. Int J Tuberc Lung Dis 2019; 21:1300-1306. [PMID: 29297451 DOI: 10.5588/ijtld.17.0232] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING A tertiary care academic medical centre. OBJECTIVE To evaluate the clinical usefulness of C-X-C motif chemokine receptor 3 (CXCR3) ligands in tuberculous pleural effusion (TPE). DESIGN We recruited 336 patients with pleural effusion due to various causes. Concentrations of interferon-gamma (IFN-γ) and the CXCR3 ligands CXCL9 and CXCL11 were determined using enzyme immunoassays; adenosine deaminase (ADA) activity was measured in pleural fluid and serum. RESULTS TPE was diagnosed in 106 patients. Non-TB conditions included lung cancer (n = 95), para-pneumonic effusion (n = 52), non-lung malignancy (n = 30), other exudate (n = 24) and transudate (n = 29) disorders. All marker levels in serum samples and pleural fluid were significantly higher in the TPE group. Analyses of receiver operating characteristic curves for differentiating TPE from non-TB effusions produced the following results for the area under the curve (AUC) for CXCL9, CXCL11, IFN-γ and ADA, respectively: 0.982, 0.952, 0.982, and 0.952. Marker AUCs in lymphocytic exudates were also high. Combining the levels of CXCL9, IFN-γ and ADA in pleural fluid improved the diagnostic performance. Serum levels of CXCL9 had the highest AUC (0.848) for diagnosing TPE. CONCLUSION Levels of CXR3 ligands in pleural effusion are useful for diagnosing TPE.
Collapse
Affiliation(s)
- W Chung
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| | - Y Jung
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| | - K Lee
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| | - J Park
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| | - S Sheen
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| | - K Park
- Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
| |
Collapse
|
133
|
Nguyen P, Makris A, Hennessy A, Jayanti S, Wang A, Park K, Chen V, Nguyen T, Lo S, Xuan W, Leung M, Badie T, Xu J, Kadappu K, Kachwalla H, Gibbs O, Faour A, Kee A, Rajaratnam R, Leung D, French J, Juergens C. Standard Versus Ultrasound-Guided Radial and Femoral Access (SURF) - A Randomised Controlled Trial. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.690] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
134
|
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han J, Hida T, Moro-Sibilot D, Conkling P, Gandara D, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer 2019; 107:124-132. [DOI: 10.1016/j.ejca.2018.11.020] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 11/09/2018] [Indexed: 01/05/2023]
|
135
|
Nguyen P, Makris A, Hennessy A, Park K, Chen V, Jayanti S, Juergens C. Ultrasonic Assessment of Subclinical Radial Artery Stenosis After Transradial Angiography. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
136
|
Nguyen P, Makris A, Hennessy A, Jayanti S, Wang A, Park K, Chen V, Juergens C. Outcomes in Femoral Access Patients with Large Abdominal Circumference. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
137
|
Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 2018; 26:815-820. [PMID: 30556120 DOI: 10.1245/s10434-018-7059-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2018] [Indexed: 01/26/2023]
Abstract
BACKGROUND OncotypeDX recurrence score (RS)® has been found to predict recurrence and disease-free survival in patients with node negative breast cancer. Whether RS is useful in guiding locoregional therapy decisions is unclear. We sought to evaluate the relationship between RS and lymph node burden. METHODS Patients with invasive breast cancer who underwent sentinel lymph node dissection from 2010 to 2015 were identified from a prospectively maintained database. Patients were excluded if they were clinically node positive or if they received neoadjuvant chemotherapy. RS was classified as low (< 18), intermediate (18-30), or high (> 30). The association between RS, lymph node burden, and disease recurrence was evaluated. Statistical analyses were performed in R version 3.4.0; p < 0.05 was considered significant. RESULTS A positive SLN was found in 168 (15%) of 1121 patients. Completion axillary lymph node dissection was performed in 84 (50%) of SLN-positive patients. The remaining 84 (50%) patients had one to two positive SLNs and did not undergo further axillary surgery. RS was low in 58.5%, intermediate in 32.6%, and high in 8.9%. RS was not associated with a positive SLN, number of positive nodes, maximum node metastasis size, or extranodal extension. The median follow-up was 23 months. High RS was not associated with locoregional recurrence (p = 0.07) but was significantly associated with distant recurrence (p = 0.0015). CONCLUSIONS OncotypeDX RS is not associated with nodal burden in women with clinically node-negative breast cancer, suggesting that RS is not useful to guide decisions regarding extent of axillary surgery for these patients.
Collapse
Affiliation(s)
- S E Tevis
- Department of Surgery, University of Colorado, Aurora, CO, USA
| | - R Bassett
- Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - I Bedrosian
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - C H Barcenas
- Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - D M Black
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A S Caudle
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - S M DeSnyder
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - E Fitzsullivan
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - K K Hunt
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - H M Kuerer
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A Lucci
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - F Meric-Bernstam
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - E A Mittendorf
- Department of Surgery, Brigham and Women's Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA
| | - K Park
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - M Teshome
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - A M Thompson
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - R F Hwang
- Department of Breast Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
| |
Collapse
|
138
|
Nugrahaeningtyas E, Park K, Baek C. PSVII-26 Greenhouse Gas Emission Intensities of Indonesian Livestock Sector with Accessible Indonesian Data. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - K Park
- Kangwon National University,Chuncheon, Republic of Korea
| | - C Baek
- Korea Institute of Industrial Technology,Cheonan, South Korea
| |
Collapse
|
139
|
Park K, Lee J, Sakai H, Lee K, Ohe Y, Kim S, Fukuhara T, Kang J, Yu C, Daga H, Hotta K, Yokoyama T, Tanaka H, Takeda M, Hellmann M, Sheng J, Nathan F, Yang R, Nishio M. OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 mut/Mb): Results From CheckMate 227. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
140
|
Freitas H, Park K, Kim DW, Tiseo M, Hochmair M, Chang GC, Shi YK, Moran T, Chen Y, Laskin J, Solomon B, Miranda M, Rigas J, Cheema P, Kim SW. ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
141
|
Lee JS, Cho B, Kim DW, Park K, Kang J, Yoo S, Lee S, Kim C, Jang S, Kim Y, Yoon HK, Kim SW. A real-world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
142
|
Ahn S, Choi J, Lee H, Park K, Suh C, Kim J. Monte Carlo Simulation and Measurement for Improving Dose Uniformity of Total Skin Electron Beam Therapy with Three Ports. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
143
|
Provencio M, Cheema P, Vansteenkiste J, Cho B, Zhou C, Yu J, Martin C, Park K, He Y, Hu Y, Vicente D, Miranda M, Rigas J, de Marinis F. ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy446.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
144
|
Viteri S, Chang GC, Chiari R, Cho B, Ciardiello F, Curigliano G, Hida T, Lee D, Lim W, Lin CC, Martinez A, Murakami H, Natsume I, Nishio M, Paz-Ares L, Soo R, Cattan V, Gandossi E, Heck H, Park K. Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
145
|
Cho B, Lee JS, Han JY, Cho E, Haura E, Lee K, Bauml J, Sanborn R, Curtis M, Attiyeh E, Haddish-Berhane N, Bae K, Knoblauch R, Sherman L, Lorenzi M, Park K. JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.118] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
146
|
Cho J, Hyeon J, Choi Y, Sun J, Lee S, Ahn J, Park K, Ahn M. P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
147
|
Kim H, Ahn Y, Kim J, Pyo H, Noh J, Sun J, Ahn J, Ahn M, Park K, Choi Y, Kim J, Zo J, Shim Y, Han J, Hyun S, Choi J. P2.01-57 Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
148
|
Jung H, Park K, Sun JM, Lee S, Ahn J, Ahn MJ, Park S. NSCLC with well controlled extra-cranial disease but uncontrolled brain metastases. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
149
|
Besse B, Subbiah V, Drilon A, Shah M, Wirth L, Bauer T, Velcheti V, Lakhani N, Boni V, Solomon B, Johnson M, Park K, Patel J, Cabanillas M, Sherman E, Zhu E, Gordon K, Ebata K, Tuch B, Oxnard G. Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
150
|
Park K, Ahn M, Lee S, Kim H, Hong M, Millington D, Curtis M, Triantos S, Chaplan S, Haddish-Berhane N, Knoblauch R, Aguilar Z, Laquerre S, Lorenzi M, Cho B. OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.292] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|